Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery (MICS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Medtronic Cardiovascular
ClinicalTrials.gov Identifier:
NCT01334866
First received: April 5, 2011
Last updated: November 3, 2013
Last verified: November 2013
History of Changes
Results First Received: August 9, 2013  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Arteriosclerosis of Coronary Artery Bypass Graft
Intervention: Procedure: Minimally invasive coronary artery bypass graft surgery

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
A total of 91 subjects were enrolled, with 89 subjects receiving the study treatment. The first subject was enrolled on December 30, 2009 and the last subject was enrolled on October 4, 2012. Of the 89 subjects treated with the study procedure, 72 subjects completed the 6 month follow-up primary endpoint visit.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Minimally Invasive Coronary Artery Bypass Grafting 91 subjects were enrolled, with 89 subjects receving the study treatment. Of the 89 subjects treated with the study procedure, 72 subjects completed the 6 month follow-up primary endpoint visit.

Participant Flow:   Overall Study
    Minimally Invasive Coronary Artery Bypass Grafting  
STARTED     91 [1]
COMPLETED     72  
NOT COMPLETED     19  
Withdrawal by Subject                 10  
Lost to Follow-up                 3  
Physician Decision                 3  
medically necessary prior to procedure                 2  
medically necessary post-procedure                 1  
[1] 91 subjects were enrolled in the study; with 89 subjects receiving the study treatment.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Study Completion Cohort 91 subjects were enrolled, with 89 subjects receving the study treatment. Of the 89 subjects treated with the study procedure, 72 subjects completed the 6 month follow-up primary endpoint visit.

Baseline Measures
    Study Completion Cohort  
Number of Participants  
[units: participants]
 		  91  
Age  
[units: years]
Mean ± Standard Deviation 		  64.1  ± 8.3  
Gender  
[units: participants]
 		 
Female     10  
Male     81  
Region of Enrollment  
[units: participants]
 		 
United States     45  
Canada     46  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Technical Success (Graft Patency) in a MICS Approach   [ Time Frame: At time of procedure (day 1) ]
  Show Outcome Measure 1

2.  Primary:   Procedural Success in a MICS Approach   [ Time Frame: At time of procedure (day 1) ]
  Show Outcome Measure 2

3.  Primary:   Patency of the Index Graft at 6 Months   [ Time Frame: 6 months post-procedure ]
  Show Outcome Measure 3

4.  Primary:   Composite Major Adverse Event Rate (Early)   [ Time Frame: During procedure (day 1) and within 30 days post-procedure or hospital discharge, whichever is longer (throughout 6 month evaluation) ]
  Show Outcome Measure 4

5.  Secondary:   Composite Major Adverse Event Rate (Late)   [ Time Frame: After 30 days post-procedure or hospital discharge, whichever is longer through the 6-Month evaluation ]
  Show Outcome Measure 5


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Kristin Lawman
Organization: Medtronic, Inc.
phone: 763-514-9809
e-mail: kristin.j.lawman@medtronic.com


No publications provided by Medtronic Cardiovascular

Publications automatically indexed to this study:


Responsible Party: Medtronic Cardiovascular
ClinicalTrials.gov Identifier: NCT01334866     History of Changes
Other Study ID Numbers: D03782
Study First Received: April 5, 2011
Results First Received: August 9, 2013
Last Updated: November 3, 2013
Health Authority: United States: Institutional Review Board
Canada: Ethics Review Committee